Subtype
Diffuse Glioma
CI-CAN-00002519Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002519Explore in graph →
Clinical trials
2,805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01514201 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2019 | clinicaltrials |
| NCT00423735 | Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 3 | Jul 24, 2019 | clinicaltrials |
| NCT01403610 | Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab | completed | Phase 2 | 28 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT03741244 | TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT | unknown | Phase 2 | 211 | The Second Hospital of Hebei Medical UniversityOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT04004975 | Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib | unknown | Phase 1 / Phase 2 | 50 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 2, 2019 | clinicaltrials |
| NCT00262730 | Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM | completed | Phase 2 | 97 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT01564914 | A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma(105GM201) | completed | Phase 2 | 22 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Jun 12, 2019 | clinicaltrials |
| NCT01116661 | Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain(ALA) | terminated | Phase 2 | 199 | University of California, San FranciscoOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT01497860 | Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas | completed | Phase 2 | 13 | Eugene HwangOTHER | 1 | May 20, 2019 | clinicaltrials |
| NCT02120287 | Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme | completed | Phase 2 | 16 | Ajay NiranjanOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT00576537 | Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors | completed | Phase 2 | 50 | Cedars-Sinai Medical CenterOTHER | 1 | May 3, 2019 | clinicaltrials |
| NCT03916757 | V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer(GBM) | unknown | Phase 2 | 20 | Immunitor LLCINDUSTRY | 1 | Apr 17, 2019 | clinicaltrials |
| NCT00093964 | Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) | completed | Phase 2 | 81 | EMD SeronoINDUSTRY | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00961090 | Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery | completed | Phase 2 | 72 | Matthew R QuigleyOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT01209442 | Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme | completed | Phase 2 | 30 | University of Colorado, DenverOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT03181581 | Improving Ultrasound Images in Brain Tumour Surgery With the Use of an Acoustic Coupling Fluid Mimicking Brain Tissue. | terminated | Phase 2 | 5 | St. Olavs HospitalOTHER | 1 | Apr 10, 2019 | clinicaltrials |
| NCT00902577 | MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Apr 8, 2019 | clinicaltrials |
| NCT00509821 | Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma | completed | Phase 2 | 60 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02395692 | Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2019 | clinicaltrials |
| NCT00441142 | Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors(Zactima) | completed | Phase 1 / Phase 2 | 119 | Patrick Y. Wen, MDOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02209428 | A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas | unknown | Phase 2 | 54 | Huashan HospitalOTHER | 1 | Feb 21, 2019 | clinicaltrials |
| NCT01186406 | Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 41 | Duke UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01044966 | A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma | terminated | Phase 1 / Phase 2 | 12 | Medical University of South CarolinaOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT01562197 | A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma(AxiGII) | completed | Phase 2 | 56 | Bart NeynsOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT03291314 | Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma(GliAvAx) | completed | Phase 2 | 52 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01846871 | Tivozanib for Recurrent Glioblastoma | completed | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT03746288 | To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM) | unknown | Phase 2 | 60 | CANbridge Life Sciences Ltd.INDUSTRY | 0 | Nov 19, 2018 | clinicaltrials |
| NCT00038441 | Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00038493 | Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme | completed | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT02850744 | Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients | terminated | Phase 2 | 10 | PIQUR Therapeutics AGINDUSTRY | 1 | Oct 19, 2018 | clinicaltrials |
| NCT00329719 | Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 115 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02253212 | Safety of BBB Opening With the SonoCloud(SONOCLOUD) | completed | Phase 1 / Phase 2 | 27 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT00323115 | Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 11 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Oct 10, 2018 | clinicaltrials |
| NCT00433381 | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 123 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01868906 | FMISO-PET in Brain Tumors and SCS Effect(FMISOPETSCS) | terminated | Phase 2 | 6 | Bernardino Clavo, MD, PhDOTHER | 1 | Aug 24, 2018 | clinicaltrials |
| NCT01112527 | PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma | completed | Phase 2 | 58 | Massachusetts General HospitalOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT00782626 | Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00679354 | Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 2 | Aug 1, 2018 | clinicaltrials |
| NCT01266031 | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2018 | clinicaltrials |
| NCT01575275 | Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme | terminated | Phase 2 | 8 | Michael Vogelbaum, MD, PhDOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT02698280 | Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma | completed | Phase 2 | 23 | Huashan HospitalOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT02478164 | Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT02233049 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication(BIOMEDE) | unknown | Phase 2 | 250 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 23, 2018 | clinicaltrials |
| NCT00749723 | Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children(HIT-REZ-2005) | completed | Phase 2 / Phase 3 | 174 | University Hospital, BonnOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01836549 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | terminated | Phase 2 | 43 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00107003 | GW572016 to Treat Recurrent Malignant Brain Tumors | completed | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01229644 | Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas | terminated | Phase 2 | 10 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 5, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Aug 13, 2019source: clinicaltrials